ReviewMedicina (Kaunas, Lithuania)2023
Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson's Disease: An Updated Review.
Review in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Non-invasive brain stimulation combined with three rehabilitation approaches for cognitive and emotional well-being in Parkinson's patients.Frontiers in neurology · 2025Pooled it
- Efficacy of acupuncture versus sham acupuncture on generalized anxiety disorder: a meta-analysis of randomized controlled trials.Frontiers in neurology · 2025Pooled it
- An overview of systematic reviews of acupuncture for Parkinson's disease.Frontiers in neuroscience · 2024Pooled it
- Memantine as an Adjunctive Treatment for Residual Anxiety and Agitation in Early Parkinson's Disease With Depression: A Case Report.Neuropsychopharmacology reports · 2026Article
- Trazodone for management of depression in Parkinson's disease: expert opinion and proposal for a treatment algorithm.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice.Movement disorders clinical practice · 2026Article
- Diagnosis and Management of Parkinson Disease in Individuals with Pre-Existing Mood Disorders.International journal of environmental research and public health · 2026Review
- Effects of Whole-Body Cryostimulation on Stress Biomarkers and Psychological Well-Being in Parkinson's Disease: A Pilot Study.Journal of clinical medicine · 2026Article
- Efficacy and safety of adjunctive acupuncture for depression and motor symptoms in Parkinson's disease: study protocol for a randomized controlled trial.Frontiers in psychiatry · 2026Article
- The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms.International journal of molecular sciences · 2025Review
- Mental Health and Well-Being of Residents with Parkinson's Disease in Care Homes: A Scoping Review.Healthcare (Basel, Switzerland) · 2025Review
- FGF21 confers neuroprotection in Parkinson's disease by activating the FGFR1-sirt1 pathway.Cellular & molecular biology letters · 2025Article
- The impact of musical intervention during fetal and infant stages on social behavior and neurodevelopment in mice.Translational psychiatry · 2025Article
- Levodopa-Carbidopa-Entacapone Intestinal Gel for Advanced Parkinson's Disease-Results from a Monocentric Study Evaluating Both Motor and Non-Motor Manifestations.Biomedicines · 2025Article
- Fears and uncertainties of people with Parkinson's disease.Journal of Parkinson's disease · 2025Article
- [Research progress on repetitive transcranial magnetic stimulation for improving depression in Parkinson's disease].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2025Review
- Benefits of a 12-week psychotherapy course for people with Parkinson's disease: a service improvement project.Journal of neurology · 2025Article
- Review
- Psychiatric Disorders and Cognitive Fluctuations in Parkinson's Disease: Changing Approaches in the First Decades of the 21st Century.Brain sciences · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression represents one of the most common non-motor disorders in Parkinson's disease (PD) and it has been related to worse life quality, higher levels of disability, and cognitive impairment, thereby majorly affecting not only the patients but also their caregivers. Available pharmacological therapeutic options for depression in PD mainly include selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and tricyclic antidepressants; meanwhile, agents acting on dopaminergic pathways used for motor symptoms, such as levodopa, dopaminergic agonists, and monoamine oxidase B (MAO-B) inhibitors, may also provide beneficial antidepressant effects. Recently, there is a growing interest in non-pharmacological interventions, including cognitive behavioral therapy; physical exercise, including dance and mind-body exercises, such as yoga, tai chi, and qigong; acupuncture; therapeutic massage; music therapy; active therapy; repetitive transcranial magnetic stimulation (rTMS); and electroconvulsive therapy (ECT) for refractory cases. However, the optimal treatment approach for PD depression is uncertain, its management may be challenging, and definite guidelines are also lacking. It is still unclear which of these interventions is the most appropriate and for which PD stage under which circumstances. Herein, we aim to provide an updated comprehensive review of both pharmacological and non-pharmacological treatments for depression in PD, focusing on recent clinical trials, systematic reviews, and meta-analyses. Finally, we discuss the pharmacological agents that are currently under investigation at a clinical level, as well as future approaches based on the pathophysiological mechanisms underlying the onset of depression in PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.